Chronic kidney disease (CKD) is one of the major public health concerns in recent years due to its adverse clinical outcomes which include cardiovascular disease (CVD), end-stage renal disease (ESRD), and mortality (1,2). CKD is most commonly attributed to diabetes mellitus (DM) and hypertension (HTN) (1). Most patients with CKD are asymptomatic. They are identified during routine blood or urine tests, less frequently as an incidental finding (1).

Clinical features of the disease become apparent only during later stages of CKD during which the patients may require hemodialysis or renal replacement therapy (3). Early detection of CKD is hence essential to prevent disease progression and initiate treatment protocols.

CKD is defined as the presence of abnormalities in the structure or function of the kidneys persisting for more than 3 months. Once diagnosed, it is important to determine the stage of CKD based on the GFR and urine albumin creatinine ratio (ACR) to predict the prognosis 1,4.

At present, most of the clinicians and clinical laboratories report eGFR based on SCr levels using GFR estimating equations such as Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) and Modification of Diet in Renal Disease (MDRD) equations. This has eliminated the need for performing direct measurement of GFR which is considered expensive and laborious (1).

Estimation of GFR based on SCr alone is not ideal. SCr level is influenced by various factors such as muscle mass, variations in filtration based on age, renal tubular secretion, drug intake, analytical factors, and extrarenal clearance (5). In order to overcome these limitations, extensive research has been carried out over years to find an alternate biomarker.

Among the several novel biomarkers discovered for the detection of impaired renal function, serum cystatin C (SCysC) has gained importance. Human cystatin C (CysC) is a low molecular weight cysteine protease inhibitor produced by all nucleated cells. It is filtered freely in the glomerulus, gets reabsorbed in the proximal...
tubules and does not get excreted in the renal tubules as it is completely degraded (6). SCysC is considered to be better than SCr in the estimation of renal function as it is not influenced by age, gender, nutritional status, and body size (7). Unlike SCr, SCysC is more useful in diagnosing a mild decrease in GFR, i.e., 60-80 mL/min/1.732 m^2 (8). Therefore, SCysC has been proposed to be a promising marker that can be utilized for the early diagnosis of nephropathy.

This study was undertaken to compare the levels of SCysC and SCr in CKD patients and apparently healthy controls.

Materials and Methods

This study was carried out at a tertiary care hospital. Subjects aged between 35-70 years, including both genders, diagnosed with CKD by the Nephrologist as per the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines (9) were selected as cases. Subjects with a history of liver disease, thyroid dysfunction, malignancy, and muscular dystrophies as well as pregnant women were excluded from the study. Age and gender-matched apparently healthy volunteers were selected as controls. Elicitation of the relevant history, clinical examination, and anthropometric measurements were carried out in all subjects. Fasting venous blood specimens were collected from the subjects in plain vacutainers from the antecubital vein. The sera were obtained by subjecting the venous blood samples to centrifugation at 3000 rpm for 10 minutes. Aliquots of sera were stored at -20°C until assayed. SCysC and SCr were estimated using the particle-enhanced immunoturbidimetric method and modified Jaffe's method, respectively. Biochemical analyses were done using Roche cobas c311 automated analyzer. In this study, 0.7-1.4 mg/dL and 0.47-1.09 mg/L were regarded as normal reference levels for SCr and SCysC, respectively, according to the reagent kit instructions. The eGFR was calculated using CKD EPI 2009 equation (10) based on SCr levels as follows:

eGFR = 141 x min (SCr/κ, 1)^α x max (SCr /κ , 1)^-1.209 x 0.993κ powerless x 1.018 [if female] x 1.159 [if Black]

Where, eGFR = mL/min/1.73 m^2, SCr (serum creatinine) = mg/dL, κ= 0.7 (females) or 0.9 (males), α= -0.329 (females) or -0.411 (males), min = minimum of SCr/κ or 1, max = maximum of SCr/κ or 1, age is in years

Statistical analysis was done using SPSS version 20.0. The normality of the data was tested using Kolmogorov Smirnov test. Qualitative data were represented as frequency and percentage. As SCysC, SCr, and eGFR followed skewed distribution, the values were represented as median and interquartile range. Comparison between descriptive data was done using Mann-Whitney U test. Pearson’s correlation test was used to study the correlation between the variables. Statistical significance was considered at P<0.05.

Results

The total number of participants in the study was 160 subjects including 120 cases and 40 controls. The results of the biochemical analysis of the study subjects are depicted in Table 1. Of the 120 CKD cases, 26.7% (n = 32) underwent dialysis.

The CKD cases were further classified into stages based on eGFR as per the KDOQI guidelines (9). As the number of CKD cases belonging to Stages 1 and 2 was less, the two stages were grouped together. The biochemical parameters were compared as shown in Table 2.

Further evaluations were performed on CKD cases to study the distribution of elevated biochemical parameters (Figure 1). In this study, 1.4 mg/dL and 1.09 mg/L were regarded as upper limits of reference intervals for SCr and SCysC, respectively, based on the reagent kit instructions. It is interesting to note that in the group comprising of subjects with Stages 1 and 2 CKD (eGFR ≥ 60 mL/min/1.732 m^2), the SCr levels were within the normal reference range in all, while SCysC was elevated in 96.8% (n = 30) of them. Among stage 3 patients (eGFR 30-59 mL/min/1.732 m^2), SCr and SCysC levels were elevated in 79.3% (n = 23) and 100% (n = 29) of the cases, respectively. Among stages 4 and 5 patients (eGFR < 30 mL/min/1.732 m^2), both SCr and SCysC levels were elevated in all cases. Both SCr (r = -0.724, P < 0.001) and serum CysC (r = -0.800, P < 0.001) showed a negative correlation with eGFR (Figures 2 and 3). Serum CysC correlated positively with SCr (r = 0.887, P < 0.001), which was statistically significant (Figure 4).

Discussion

CysC is a low molecular weight protein belonging to the human cystatin family, comprising of twelve proteins (11,12). CysC was first suggested as an endogenous marker of GFR in 1985 by Simonsen et al (13). CysC is present in almost all body fluids and tissues which include the brain, liver, kidney, placenta, and seminal vesicles (14). CysC is cleared from the circulation
through the kidneys. Due to its low molecular weight as well as high isoelectric point, it is freely filtered by the glomerulus, reabsorbed, and subsequently catabolized in the proximal renal tubules (15,16). Its half-life is about 1.5 hours (17).

The current study was carried out to demonstrate the usefulness of estimating serum CysC in CKD patients. The present study showed that SCysC and SCr levels were significantly higher in CKD subjects compared to controls \((P < 0.001)\). These findings were similar to those of the previous studies done by Bhoi et al (18) and Dhupper et al (19), demonstrating high levels of SCysC and SCr in progressive chronic renal disease compared to controls.

The levels of SCysC and SCr were compared between controls and patients with various stages of CKD. There was a significant increase in both parameters across the

| Parameters                  | CKD Cases (n=120) | Controls (n=40) |
|-----------------------------|------------------|----------------|
| Serum creatinine (in mg/dL) | 2.26** (1.21–4.10) | 0.80 (0.71–0.96) |
| Serum cystatin C (mg/L)     | 2.34** (1.65–3.45) | 0.96 (0.83–1.04) |
| Estimated GFR (mL/min/1.73 m²) | 28.50** (14.50–61.50) | 94.50 (84.25–109.75) |
| Serum creatinine- eGFR ratio | 0.0845** (0.0209–0.2849) | 0.0085 (0.0067–0.0086) |
| Serum cystatin eGFR ratio   | 0.0872** (0.0306–0.2110) | 0.0098 (0.0086–0.0118) |

** \(P < 0.001\)

CysC was proposed as an alternative biomarker for GFR estimation several years ago. SCysC has been documented to be more reliable than SCr. Despite this, SCysC is still not implemented as a routine test in clinical practice (23).

In 2018, a survey was conducted on 369 participants comprising of leading nephrologists and intensivists. About 25% of the study participants believed that SCr, as a routine laboratory test, should be replaced with a new biomarker and only 15% used CysC in their clinical practice (24).

The incorporation of CysC in GFR estimating equations has proved to be beneficial especially in children, older adults, and persons with acute illness since SCr estimation can be highly unpredictable with extremes of age and illness (23). In general, SCysC based eGFR equations have

Figure 2. Correlation of Serum Creatinine With eGFR Among the Study Subjects.

Figure 3. Correlation of Serum Cystatin C With eGFR Among the Study Subjects.

Table 1. Comparison of Biochemical Parameters and eGFR Between Cases and Controls
Shetty et al compiled the references, proofread, and edited the manuscript. SR proofread and edited the manuscript. RRB proofread and edited the manuscript. All authors read and approved the manuscript.

Conflict of Interest Disclosures
The authors declare that they have no conflict of interest.

Ethical Issues
This study was approved by Institutional Ethical Committee, K.S Hegde Medical Academy, Nitte (deemed to be) University, Mangalore, Karnataka, India (INST/EC/073/2014-15). Informed consent was obtained from all participants included in the study.

References
1. Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. JAMA. 2019;322(13):1294-304. doi: 10.1001/jama.2019.14745.
2. Romagnani P, Remuzzi G, Glasscock R, Levin A, Jager KJ, Tonelli M, et al. Chronic kidney disease. Nat Rev Dis Primers. 2017;3:17088. doi: 10.1038/nrdp.2017.88.
3. Kinchen KS, Sadler J, Fink N, Brookmeyer R, Klag MJ, Levey AS, et al. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med. 2002;137(6):479-86. doi: 10.1097/00000348-137-6-200209170-00007.
4. Strand SS. Comments on ‘KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease’. Kidney Int. 2013;84(3):622-3. doi: 10.1038/ki.2013.243.
5. Delanaye P, Cavalier E, Pottel H. Serum creatinine: not so simple! Nephron. 2017;136(4):302-8. doi: 10.1159/000469669.
6. Chew JS, Saleem M, Florkowski CM, George PM. Cystatin C--a paradigm of evidence based laboratory medicine. Clin Biochem Rev. 2008;29(2):47-62.
7. Benoit SW, Ciccia EA, Devarajan P, Cystatin C as a biomarker of chronic kidney disease: latest developments. Expert Rev Mol Diagn. 2020;20(10):1019-26. doi: 10.1080/14737519.2020.1768849.
8. Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int. 1985;28(5):830-8. doi: 10.1038/ki.1985.205.
9. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-266.
10. Levey AS, Stevens LA. Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis. 2010;55(4):622-7. doi: 10.1016/j.ajkd.2010.02.337.
11. Brzin J, Popovic T, Turk V, Borchart U, Machleidt W. Human cystatin, a new protein inhibitor of cysteine proteinases.

Table 2. Comparison of Biochemical Parameters and eGFR Between Patients With Different Stages of CKD and Controls

| Parameters                          | Controls (n = 40) | Stages 1 and 2 (n = 31) | Stage 3 (n = 29) | Stage 4 (n = 30) | Stage 5 (n = 30) |
|-------------------------------------|------------------|-------------------------|-----------------|-----------------|-----------------|
| Serum creatinine (mg/dL)            | 0.80 (0.71-0.96) | 1.00** (0.89-1.12)     | 1.71** (1.44-2.06) | 2.92** (2.48-3.55) | 7.25** (5.77-1.08) |
| Serum cystatin C (mg/L)             | 0.96 (0.83-1.04) | 1.35** (1.18-1.64)     | 1.93** (1.72-2.39) | 2.69** (2.31-3.14) | 4.69** (3.95-5.49) |
| Estimated GFR (mL/min/1.732 m²)     | 94.50 (84.25-109.75) | 79.00** (69.00-87.00) | 42.00** (35.50-48.50) | 21.50** (18.00-25.25) | 7.50** (5.00-9.25) |
| Serum creatinine-eGFR ratio         | 0.0085 (0.0067-0.0086) | 0.0125** (0.0100-0.0166) | 0.0364** (0.0278-0.0585) | 0.1407** (0.0983-0.1961) | 0.8775** (0.6249-2.2470) |
| Serum cystatin C-eGFR ratio         | 0.0098 (0.0086-0.0118) | 0.0184** (0.0137-0.0220) | 0.0465** (0.0388-0.0548) | 0.1325** (0.0995-0.1667) | 0.6200** (0.4185-1.1079) |

Comparison with the previous stage; **P<0.001.

Figure 4. Correlation of Serum Cystatin C With Serum Creatinine Among the Study Subjects.

Conclusion
The current study established that SCysC is increased considerably in CKD patients. Stagewise increase in SCysC was observed which was comparable with SCR. Estimation of SCysC especially in CKD patients with mild to moderate reduction in GFR is useful since SCR may appear normal. The limitations of the study were the small sample size and the inability to quantify albuminuria due to certain constraints.

Acknowledgements
Nil.

Authors’ Contributions
SS conceived, designed, and supervised the study. JD collected the data, performed data analysis, and wrote the manuscript. TR performed data analysis, and wrote the manuscript. TR conceived, designed, and supervised the study. JD collected the data, performed data analysis, and wrote the manuscript. TR conceived, designed, and supervised the study. JD collected the data, performed data analysis, and wrote the manuscript.
12. Grubb A, Löfberg H. Human gamma-trace, a basic microprotein: amino acid sequence and presence in the adenohypophysis. Proc Natl Acad Sci U S A. 1982;79(9):3024-7. doi: 10.1073/pnas.79.9.3024.

13. Simonsen O, Grubb A, Thyssell H. The blood serum concentration of cystatin C (gamma-trace) as a measure of the glomerular filtration rate. Scand J Clin Lab Invest. 1985;45(2):97-101. doi: 10.3109/00365518509160980.

14. Filler G, Bökenkamp A, Hofmann W, Le Bricon T, Martínez-Brú C, Grubb A. Cystatin C as a marker of GFR--history, indications, and future research. Clin Biochem. 2005;38(1):1-8. doi: 10.1016/j.clinbiochem.2004.09.025.

15. Jacobsson B, Lignelid H, Bergerheim US. Transthyretin and cystatin C are catabolized in proximal tubular epithelial cells and the proteins are not useful as markers for renal cell carcinomas. Histopathology. 1995;26(6):559-64. doi: 10.1111/j.1365-2559.1995.tb00275.x.

16. Tenstad O, Roald AB, Grubb A, Aukland K. Renal handling of radiolabelled human cystatin C in the rat. Scand J Clin Lab Invest. 1996;56(5):409-14. doi: 10.3109/00365519609088795.

17. Knight EL, Verhave JC, Spiegelman D, Hildege HL, de Zeeuw D, Cushman GC, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65(4):1416-21. doi: 10.1111/j.1523-1755.2004.00517.x.

18. Bhoi Bharat K, Maheshwari Amitkumar V, Sadariya Bhavesh R, Shaikh Sahema M, Panchal Mittal A. Comparison of estimated glomerular filtration rate using different analytes in chronic kidney disease patients. Int J Res Med. 2015;4(3):8-13.

19. Dhupper V, Ghalaut VS, Kulshrestha MR, Bhadra J, Yadav U, Mahor DS. Evaluation of cystatin C as a marker of estimated glomerular filtration rate (eGFR) in different stages of chronic kidney disease (CKD). Sch Acad J Biosci. 2015;3(4):328-34.

20. Lubowitz H, Slatopolsky E, Shankel S, Rieselbach RE, Bricker NS. Glomerular filtration rate. Determination in patients with chronic renal disease. JAMA. 1967;199(4):252-6. doi: 10.1001/jama.1967.199.4.252.

21. Rule AD, Bergstralh EJ, Slezak JM, Bergert J, Larson TS. Glomerular filtration rate estimated by cystatin C among different clinical presentations. Kidney Int. 2006;69(2):399-405. doi: 10.1038/sj.ki.500073.

22. Tsai JP, Wu SW, Hung TW, Kao WT, Hong CL, Lian JD, et al. Diagnostic performance of serum cystatin C and serum creatinine in the prediction of chronic kidney disease in renal transplant recipients. Transplant Proc. 2010;42(10):4530-3. doi: 10.1016/j.transproceed.2010.09.150.

23. Ebert N, Shlipak MG. Cystatin C is ready for clinical use. Curr Opin Nephrol Hypertens. 2020;29(6):591-8. doi: 10.1097/MNH.0000000000000638.

24. Digvijay K, Neri M, Fan W, Ricci Z, Ronco C. International survey on the management of acute kidney injury and continuous renal replacement therapies: year 2018. Blood Purif. 2019;47(1-3):113-9. doi: 10.1159/000493724.

25. Shlipak MG, Matsushita K, Årnlöv J, Inker LA, Katz R, Polkinghorne KR, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013;369(10):932-43. doi: 10.1056/NEJMoa1214234.